×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: LY03020 - Luye Pharma Phase 1 Trial
clinical
3,130 words
KG: ent-clin-6ff51c57
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
phase-1
alzheimers
schizophrenia
Contents
LY03020 - Luye Pharma Phase 1 Trial
Knowledge Graph
Related Hypotheses (7)
Phase-Separated Organelle Targeting
Score: 0.52
Stress Granule Phase Separation Modulators
Score: 0.49
RNA Granule Nucleation Site Modulation
Score: 0.48
Cryptic Exon Silencing Restoration
Score: 0.46
Cross-Seeding Prevention Strategy
Score: 0.45
Glycine-Rich Domain Competitive Inhibition
Score: 0.43
Serine/Arginine-Rich Protein Kinase Modulation
Score: 0.42
Show 2 more
Related Analyses (4)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Related Experiments (1)
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40